Mar 13, 2026 by Adria CiminoGot $1,000? 3 Stocks to Buy Now While They're On SaleThese players are present in the tech and consumer goods markets.
Mar 13, 2026 by Will HealyThe Artificial Intelligence (AI) Software Sell-Off Created a Rare Buying Opportunity. Here Are 3 Stocks to Grab in 2026.Fears about artificial intelligence (AI) seem to have led to overselling in these stocks.
Mar 13, 2026 by Jonathan PoncianoEducation Stock Up 84% as One Fund Ups Stake to Nearly $6 MillionLaureate Education runs a network of universities, offering degree programs in Latin America and the U.S. through campus and online formats.
Mar 13, 2026 by Jonathan PoncianoWhat to Know About a $6 Billion Mortgage Bond ETF That Became This Fund's Largest HoldingThe First Trust Low Duration Opportunities ETF targets income and risk management through a portfolio focused on mortgage-related securities.
Mar 13, 2026 by Kailey Hagen, CFPThese 2 Years Could Be Especially Hard on Retirees' BudgetsThese two changes aren't that far off and could have a huge effect on your quality of life.
Mar 13, 2026 by Jonathan PoncianoThis Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA DecisionVera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.
Mar 13, 2026 by Neil PatelDara Khosrowshahi Just Gave Uber Investors Great NewsThe successful CEO is addressing the mobility company's biggest risk factor.
Mar 13, 2026 by Leo SunNvidia Just Dumped This AI Stock, but Here's Why That Might Be a Buying OpportunityApplied Digital lost its biggest backer, but it's still growing like a weed.
Mar 13, 2026 by Jeremy BowmanIs Adobe's CEO Transition a Red Flag or an Opportunity for Investors in 2026?After 18 years, CEO Shantanu Narayen is stepping down.
Mar 13, 2026 by Jonathan PoncianoInside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer DrugCelcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Mar 13, 2026 by Anders BylundWhy KinderCare Learning Companies Stock Plunged 39% Friday MorningKinderCare's 2026 guidance sent shares to all-time lows. Here's what went wrong.
Mar 13, 2026 by Daniel SparksDollar General Stock Dips: Time to Buy?A massive fourth-quarter earnings beat wasn't enough to impress investors after Dollar General issued a cautious outlook for the year ahead.
Mar 13, 2026 by Rich SmithWhy Angel Studios Stock Dropped TodayAngle flew high after its IPO, but its wings have since been clipped.
Mar 13, 2026 by Daniel MillerEV Investors Hoping for a Rebound Could Be Left WaitingSome investors were anxiously waiting for a signal that EV stocks could quickly rebound higher, but it would be wise to look at the bigger picture.
Mar 13, 2026 by Jonathan PoncianoPraxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its PipelinePraxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.
Mar 13, 2026 by Jennifer SaibilYou Won't Believe How Much Money Berkshire Hathaway Gets From Apple DividendsThe Buffett favorite offers growth and passive income.
Mar 13, 2026 by Matt Frankel, CFPHere Are Billionaire Steven Cohen's 5 Biggest Stock HoldingsPoint72's portfolio doesn't rely too much on any individual stocks, but it's sector-concentrated.
Mar 13, 2026 by Jake LerchSOXL vs. SSO: What Type of Investor Should Consider These Leveraged ETFs?Explore how leverage and sector focus shape the risk, volatility, and income potential of these two popular trading ETFs.
Mar 13, 2026 by John BromelsIran Fears Crushed Korean Chip Stocks. Here's 1 Thing American Memory Investors Should Watch.Samsung's loss could be Nvidia's or Micron's gain.
Mar 13, 2026 by Jonathan PoncianoThis Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 BreakthroughThis biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations.
